This Plain Language Summary of Publication from Future Cardiology summarises two studies called ORION-10 and ORION-11. Atherosclerotic cardiovascular disease (ASCVD) is a disease where the blood vessels that carry blood from the heart to other areas of the body are blocked by fatty build-up (plaque) causing a heart attack, stroke, or other problems. High levels of a molecule called low-density lipoprotein cholesterol (LDL cholesterol) in the blood can cause this fatty build-up. The ORION-10 and ORION-11 studies investigated whether a medicine called inclisiran could help to lower LDL (bad) cholesterol in participants with ASCVD, or at risk of having ASCVD.

Read the full article here.

This is a summary of the article describing the results of the ORION-10 and ORION-11 studies, which was published in the New England Journal of Medicine in April 2020. The studies included adult participants with atherosclerotic cardiovascular disease (ASCVD). ASCVD happens when the blood vessels that carry blood from the heart to other areas of the body are blocked by fatty build-up (plaque) causing a heart attack, stroke, or other problems. High levels of low-density lipoprotein cholesterol (LDL cholesterol) in the blood can cause this fatty build-up. ORION-11 also included participants who were at high risk for ASCVD due to other conditions or high cholesterol that runs in the family

The original article describing the results of the ORION-10 and ORION-11 studies was published in the New England Journal of Medicine and is titled “Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol”. You can read the original article here.